BioSpace News Archive

- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize - The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing

Health Canada is aware that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has issued an authorization for a COVID-19 vaccine manufactured by AstraZeneca.

Omnia Medical, one of the fastest growing spine organizations in the United States, today announced the addition of Jennifer Martin and Dan Rogers to the Omnia Medical team.

Beta Bionics, Inc. — a medical technology company developing the iLet®, the world’s first fully automated bionic pancreas system — today announced that Beth Brooke has been appointed to the Company’s Board of Directors.

Axial Therapeutics Inc., a clinical-stage biotechnology company dedicated to building a unique class of gut-restricted therapeutics for central nervous system (CNS) disorders and conditions, today announced that management will participate in a keynote presentation at the ACCESS CHINA Forum @JPM WEEK 2021 Conference on Tuesday, January 5, 2021 at 8:00 PM EST.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 39th Annual J.P. Morgan Healthcare Conference.

Clene Nanomedicine, Inc. (“Clene”) (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, today announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update.

Hongkong WinHealth Pharma Group CO., Ltd and Immedica Pharma AB, announce that they have entered an agreement under which WinHealth gains the exclusive commercial rights to Ravicti®, in a territory covering the Greater China Area, South Korea, Singapore, Vietnam, Indonesia, Malaysia, Philippines and Thailand.

Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19TM PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19TM PLUS Total Antibody Test

The addressable market is estimated to be $80M CDN by 2022 Tetra meets another key milestone before the end of the year